Healthcare
CSL Ltd.(CMXHF)
Live Price
Offline$74.17
+0.50% today
1Y Change
-49.68%
Window
Jun 25, 2025 → Jun 12, 2026
- Market Cap
- $43.48B
- Revenue Growth
- +4.3%
- EPS Growth
- +13.3%
- Dividend Yield
- 3.4%
Coverage: 244 bars · Jun 25, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CSL Ltd. (CMXHF) is a Healthcare stock with a market cap of $43.48B and listed on OTC. The stock last traded around $74.17 and down 49.7% across the available one-year price window (Jun 25, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +4.3%, EPS growth of +13.3%, a dividend yield of 3.4%. What stands out right now is revenue +4.3%, EPS +13.3%, free cash flow +68.9% with operating margin 25.7% and ROIC 10.4%. The dividend matters to the case here, with a current yield around 3.4%. Valuation already assumes a fairly strong business story at P/E 30.1 and price/sales 2.8. Stock Foundry combines CMXHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.3% vs +7.6% peer median
Operating Margin
Above sector median
+25.7% vs +19.4% peer median
P/E
Below sector median
30.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Feb 10, 2026 with an EPS surprise of -2.7% and a revenue surprise of -2.0%.
The operating story is still moving forward
Revenue is running at +4.3% and EPS at +13.3%, with operating margin around 25.7%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 18, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Δ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 10, 2026 | -2.7% | -4.7% | -17.7% | -21.1% |
2025 Aug 18, 2025 | -47.3% | -21.8% | -18.7% | -25.0% |
2025 Feb 11, 2025 | -42.0% | +7.1% | +2.5% | +20.7% |
Benchmark Edge
CMXHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CMXHF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CMXHF Max Drawdown
-62.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CMXHF and SPY.
Company Overview
CSL Ltd.
OTC
CSL Limited is a leading Australian multinational biotechnology company specializing in the research, development, manufacturing, and marketing of lifesaving medicines and vaccines. The company’s portfolio includes plasma-derived therapies for conditions such as hemophilia and immune deficiencies, influenza vaccines, and treatments for rare and serious diseases. CSL operates globally through its core divisions—CSL Behring, CSL Seqirus, and CSL Vifor—serving patients in over 100 countries. With a history dating back to 1916, CSL has played a pivotal role in advancing public health, including during major global health events like the COVID-19 pandemic. The company is listed on the CHI-X Market Australia – Limit Venue, providing investors access to one of the largest and most innovative biotech firms in the Asia-Pacific region. CSL’s commitment to scientific innovation and global health continues to shape the biotechnology sector and drive advancements in patient care.
- Leadership
- Mr. Gordon Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A.
- Employees
- 29.9k
- Street Address
- 655 Elizabeth Street
- Mailing
- Melbourne, VIC, 3000
- Region
- Melbourne, VIC, Australia
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 30.1
- EV/EBITDA
- 10.7
- Price/Sales
- 2.8
- Price/Book
- 2.3
Growth
- Revenue
- +4.3%
- EPS
- +13.3%
- Free Cash Flow
- +68.9%
Profitability
- Gross Margin
- 48.6%
- Operating Margin
- 25.7%
- Net Margin
- 9.2%
- ROE
- 7.6%
- ROIC
- 10.4%
Balance Sheet
- Debt/Equity
- 0.67
- Current Ratio
- 2.57
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.